HEPA (Hepion Pharmaceuticals) ROE % Adjusted to Book Value: -35.32% (As of Mar. 2026)


What is Hepion Pharmaceuticals ROE % Adjusted to Book Value?

Hepion Pharmaceuticals HEPA -0.22% ROE % Adjusted to Book Value is -35.32% as of Mar. 2026. The stock has 2 warning signs investors should review.

Hepion Pharmaceuticals's ROE % for the quarter that ended in Mar. 2026 was -143.38%. Hepion Pharmaceuticals's PB Ratio for the quarter that ended in Mar. 2026 was 4.06. Hepion Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -35.32%.

Hepion Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Hepion Pharmaceuticals ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Hepion Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hepion Pharmaceuticals ROE % Adjusted to Book Value Chart

Hepion Pharmaceuticals Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -51.60 -125.70 -61.60 0.00 -2,896.69

Hepion Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,284.89 -246.50 -147.61 -123.55 -35.32

HEPA vs AXIM, ZVSA, ISCO: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Hepion Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hepion Pharmaceuticals ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hepion Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Hepion Pharmaceuticals's ROE % Adjusted to Book Value falls into.


Hepion Pharmaceuticals ROE % Adjusted to Book Value Calculation

Hepion Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-2,056.65% / 0.71
=-2,896.69%

Hepion Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-143.38% / 4.06
=-35.32%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -35.32% mean?
Hepion Pharmaceuticals (HEPA) has a ROE % Adjusted to Book Value of -35.32% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Hepion Pharmaceuticals and its competitors.
Is Hepion Pharmaceuticals' ROE % Adjusted to Book Value too high?
Hepion Pharmaceuticals' current ROE % Adjusted to Book Value is -35.32%.
How does Hepion Pharmaceuticals' ROE % Adjusted to Book Value compare to AXIM and ZVSA?
Hepion Pharmaceuticals' ROE % Adjusted to Book Value of -35.32% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Hepion Pharmaceuticals and its competitors. Hepion Pharmaceuticals's current ROE % Adjusted to Book Value is -35.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hepion Pharmaceuticals stock overvalued right now?
Hepion Pharmaceuticals (HEPA) has a current ROE % Adjusted to Book Value of -35.32%. The current ROE % Adjusted to Book Value is -35.32%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Hepion Pharmaceuticals (HEPA), the current ROE % Adjusted to Book Value is -35.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hepion Pharmaceuticals Business Description

Address 55 Madison Avenue, Suite 400- PMB 4362, Morristown, NJ, USA, 07960
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of drug therapy for the treatment of chronic liver diseases. The company is pioneering early cancer detection solutions with a novel liquid biopsy. diagnostics. The company's mission is to redefine the early detection of hepatocellular carcinoma, moving from missed diagnoses to timely, precise intervention. It's focused on delivering non-invasive, clinically grounded liquid biopsy solutions for patients at the highest risk, particularly those living with cirrhosis.